Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2009 Mar 13

PMID 19280264

Citations 19

Authors

Judy C Boughey

Jamie Wagner

Betsy J Garrett

Lori Harker

Lavinia P Middleton

Gildy V Babiera

Funda Meric-Bernstam

Anthony Lucci

Kelly K Hunt

Isabelle Bedrosian

Affiliations

Soon will be listed here.

Abstract

Background: Patients with invasive lobular carcinoma (ILC) experience a lower pathological complete response rate to neoadjuvant chemotherapy than patients with invasive ductal carcinoma. This study was intended to evaluate the impact of neoadjuvant chemotherapy in ILC on breast-conserving surgery (BCS) rates.

Methods: Two-hundred eighty-four consecutive patients with pure ILC treated between May 1998 and September 2006 were reviewed. Surgical procedures and long-term outcomes were compared between patients receiving neoadjuvant chemotherapy and those receiving surgery first.

Results: Neoadjuvant chemotherapy was administered to 84 patients; 200 patients underwent surgery first. The mean tumor size in the neoadjuvant group (4.9 cm) was significantly larger than in patients who underwent surgery first (2.5 cm, p < 0.0001). In the neoadjuvant group, clinical complete response was seen in 10% and partial response in 59%. Overall BCS rates were 17% in the neoadjuvant group compared with 43% in the surgery-first group (p < 0.0001). When controlled for initial tumor size, there was no difference (all p > 0.05) between the groups in terms of (1) the proportion of patients who underwent an initial attempt at BCS, (2) rate of failure of BCS or (3) the proportion of patients undergoing BCS as their final procedure. With a mean follow-up of 47 months, local recurrence (LR) rates were similar between the two groups (1.2% versus 0.5%, p = 0.5).

Conclusion: The use of neoadjuvant chemotherapy does not increase the rates of breast conservation in patients with pure ILC.

Citing Articles

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.

Mukhtar R, Gottipati S, Yau C, Lopez-Tarruella S, Earl H, Hayward L NPJ Breast Cancer. 2025; 11(1):14.

PMID: 39948079 PMC: 11825822. DOI: 10.1038/s41523-025-00720-3.

Transcriptomic analysis identifies enrichment of cAMP/PKA/CREB signaling in invasive lobular breast cancer.

Puthanmadhom Narayanan S, Wedn A, Shah O, Chen J, Brown D, McAuliffe P Breast Cancer Res. 2024; 26(1):149.

PMID: 39478577 PMC: 11526681. DOI: 10.1186/s13058-024-01900-y.

Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.

van Hemert A, van Loevezijn A, Bosman A, Vlahu C, Loo C, Vrancken Peeters M Breast Cancer Res Treat. 2024; 204(3):497-507.

PMID: 38189904 DOI: 10.1007/s10549-023-07192-8.

Neoadjuvant chemotherapy for stage II-III breast cancer: a single-center experience.

El Zaher H, Fathy H, Abozeid M, Faisal M World J Surg Oncol. 2023; 21(1):314.

PMID: 37805553 PMC: 10559473. DOI: 10.1186/s12957-023-03199-z.

Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.

Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M Ann Surg Oncol. 2023; 30(12):7099-7106.

PMID: 37561345 PMC: 10562340. DOI: 10.1245/s10434-023-14075-1.

References

Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski C . Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat. 2006; 104(1):109-14. DOI: 10.1007/s10549-006-9397-3. View

Kuerer H, Newman L, Smith T, Ames F, Hunt K, Dhingra K . Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-9. DOI: 10.1200/JCO.1999.17.2.460. View

Newman L, Buzdar A, Singletary S, Kuerer H, Buchholz T, Ames F . A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002; 9(3):228-34. DOI: 10.1007/BF02573059. View

Cocquyt V, Van Belle S . Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol. 2005; 17(1):55-60. DOI: 10.1097/00001703-200502000-00010. View

Voogd A, Nielsen M, Peterse J, Blichert-Toft M, Bartelink H, Overgaard M . Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001; 19(6):1688-97. DOI: 10.1200/JCO.2001.19.6.1688. View

Wagner J, Boughey J, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F . Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg. 2009; 198(3):387-91. PMC: 4355914. DOI: 10.1016/j.amjsurg.2009.01.006. View

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S, Broglio K, Theriault R . Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2004; 23(1):41-8. DOI: 10.1200/JCO.2005.03.111. View

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A . Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002; 347(16):1227-32. DOI: 10.1056/NEJMoa020989. View

Guarneri V, Broglio K, Kau S, Cristofanilli M, Buzdar A, Valero V . Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006; 24(7):1037-44. DOI: 10.1200/JCO.2005.02.6914. View

10.

Fisher B, Anderson S, Fisher E, Redmond C, Wickerham D, Wolmark N . Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991; 338(8763):327-31. DOI: 10.1016/0140-6736(91)90475-5. View

11.

WELLINGS S, Jensen H, Marcum R . An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975; 55(2):231-73. View

12.

Mann R, Hoogeveen Y, Blickman J, Boetes C . MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat. 2007; 107(1):1-14. PMC: 2096637. DOI: 10.1007/s10549-007-9528-5. View

13.

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16(8):2672-85. DOI: 10.1200/JCO.1998.16.8.2672. View

14.

Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere J, Bouita L, Cohen-Solal C . Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006; 17(8):1228-33. DOI: 10.1093/annonc/mdl114. View

15.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

16.

. The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization. Am J Clin Pathol. 1982; 78(6):806-16. DOI: 10.1093/ajcp/78.6.806. View

17.

Mathieu M, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli J . The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004; 40(3):342-51. DOI: 10.1016/j.ejca.2003.08.015. View

18.

Cocquyt V, Blondeel P, Depypere H, Praet M, Schelfhout V, Silva O . Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003; 29(4):361-7. DOI: 10.1053/ejso.2002.1404. View